List of Excipients in Branded Drug SEEBRI NEOHALER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sunovion Pharmacueticals Inc	SEEBRI NEOHALER	glycopyrrolate	63402-815	LACTOSE MONOHYDRATE
Sunovion Pharmacueticals Inc	SEEBRI NEOHALER	glycopyrrolate	63402-815	MAGNESIUM STEARATE

SEEBRI NEOHALER Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

SEEBRI NEOHALER is a dry-powder inhaler product containing glycopyrrolate, an inhaled long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. Its excipient platform is deliberately simple: micronized glycopyrrolate bromide is blended with lactose monohydrate and filled into hard capsules for administration through the Neohaler device. The main commercial opportunities are generic capsule-and-device replication, lactose-free carrier systems, improved powder engineering, and combination inhalers that preserve glycopyrrolate’s clinical role while reducing device and formulation constraints.

What is the SEEBRI NEOHALER formulation?

SEEBRI NEOHALER contains glycopyrrolate inhalation powder in unit-dose capsules. The United States product is identified as glycopyrrolate inhalation powder, 15.6 micrograms per capsule, administered using the Neohaler inhaler.[1]

Product attribute	SEEBRI NEOHALER profile
Active ingredient	Glycopyrrolate, also called glycopyrronium bromide in some jurisdictions
Dosage form	Inhalation powder in hard capsules
Nominal capsule strength	15.6 micrograms glycopyrrolate per capsule
Administration	One capsule inhaled through the Neohaler device once daily
Primary indication	Maintenance treatment of airflow obstruction in COPD
Principal excipient	Lactose monohydrate
Capsule shell	Hard capsule, with product-specific shell composition and colorants
Device requirement	Neohaler capsule-piercing dry-powder inhaler
Sponsor	Novartis Pharmaceuticals Corporation in the United States
FDA application	NDA 207923

The low drug load creates a substantial formulation problem. The delivered glycopyrrolate dose is measured in micrograms, while the powder must have sufficient bulk, flow, dispersion and dose uniformity for reliable patient use. Lactose is therefore used as a carrier and bulking excipient rather than as a pharmacologically active component.

The product label identifies lactose monohydrate as an inactive ingredient and warns that the formulation contains a small amount of milk-protein residue.[1] That warning creates a specific opportunity for lactose-free or low-residue alternatives, although any substitute would require comparative performance and regulatory support.

How does the SEEBRI NEOHALER excipient strategy work?

The formulation depends on carrier-based dry-powder inhalation rather than a large, engineered porous particle or a propellant-based metered-dose system.

Lactose as a carrier

Lactose monohydrate performs several functions:

• It increases powder mass so the capsule contains a practically handleable quantity.
• It acts as a carrier for micronized glycopyrrolate particles.
• It supports blending and capsule filling.
• It influences powder flow, deagglomeration and emitted dose.
• It is compatible with established inhalation manufacturing processes.

The drug must detach from the lactose carrier during inhalation and reach the lower airways. Carrier morphology, particle-size distribution, surface roughness, fines content and blending energy can materially affect fine-particle dose.

Micronized glycopyrrolate

Glycopyrrolate has a low therapeutic dose, so the active pharmaceutical ingredient generally requires micronization or another particle-engineering approach. Critical quality attributes include:

• Active particle-size distribution.
• Surface area and surface energy.
• Crystallinity and polymorphic form.
• Moisture content.
• Electrostatic behavior.
• Blend uniformity.
• Fine-particle fraction.
• Delivered-dose uniformity.

A generic formulation that matches the nominal strength but changes the carrier grade or powder-energy profile may not reproduce the reference product’s aerodynamic performance.

Capsule and device interaction

SEEBRI NEOHALER is a capsule-based inhaler. The capsule is pierced inside the device, and the patient inhales the powder through the resulting openings. Capsule material, wall thickness, brittleness, moisture sensitivity and residual powder retention can affect dose delivery.

The device is therefore part of the commercial barrier. A developer cannot treat the capsule as an ordinary oral dosage-form component. The capsule must perform consistently with the Neohaler or a substitutable inhaler, and the product must demonstrate comparable delivered-dose performance across relevant flow rates.

What excipients are most relevant to SEEBRI NEOHALER alternatives?

The most commercially relevant excipient strategies are carrier replacement, carrier modification and carrier-free powder engineering.

Strategy	Candidate approach	Commercial rationale	Main technical barrier
Reference-like generic	Lactose monohydrate with comparable grade and particle distribution	Simplifies development and supports an ANDA-style pathway	Demonstrating equivalent aerodynamic performance
Lactose-reduced formulation	Lower lactose loading with engineered active particles	Reduces milk-protein and lactose concerns	Dose uniformity at very low fill mass
Lactose-free carrier	Mannitol, trehalose or another inhalation-grade sugar	Opens a differentiated label and patient segment	Safety, powder dispersion and regulatory comparability
Engineered carrier	Coated, porous or surface-modified carrier particles	Improves drug detachment and fine-particle dose	Manufacturing complexity and patent exposure
Carrier-free powder	Spray-dried or spray-freeze-dried glycopyrrolate particles	Reduces dependence on carrier detachment	Poor flow, aggregation and moisture sensitivity
Composite particle	Glycopyrrolate embedded in a matrix particle	Can improve aerosolization and content uniformity	Scale-up and stability
Moisture-protected system	Blister, foil pouch or desiccated capsule presentation	Protects powder performance in humid climates	Packaging cost and device compatibility

Mannitol is the most obvious lactose alternative because it is widely used in inhalation and parenteral products. Its different density, morphology, hygroscopicity and surface properties mean that a direct one-for-one substitution is unlikely to work. Trehalose can provide glass-forming and stabilizing properties, but its moisture behavior may complicate storage and capsule performance.

What formulation patents protect SEEBRI NEOHALER?

The relevant intellectual-property perimeter is broader than the ingredient list. It can include:

1. Glycopyrrolate particle engineering.
2. Dry-powder blends containing glycopyrrolate and a carrier.
3. Capsule filling and dose-uniformity controls.
4. Inhaler-device geometry.
5. Capsule piercing and powder-emptying mechanisms.
6. Specific dosing regimens.
7. Combination products containing glycopyrrolate.
8. Manufacturing processes and particle-size specifications.

The simple use of lactose monohydrate is unlikely to provide meaningful standalone protection. Commercial barriers are more likely to arise from the combination of active-particle properties, carrier characteristics, capsule fill, device performance and manufacturing controls.

The FDA Orange Book is the controlling source for patents listed against the United States NDA and for any listed method-of-use claims.[2] A development team should distinguish between:

• Patents listed for the reference NDA.
• Unlisted formulation or process patents.
• Expired patents.
• Patent-term-adjusted expiration dates.
• Pediatric extensions.
• Device patents.
• Foreign patents that do not affect a U.S. ANDA.

A patent family covering a glycopyrrolate formulation does not automatically block a formulation using a different carrier or a different particle-engineering process.

When does SEEBRI NEOHALER lose exclusivity?

SEEBRI NEOHALER received U.S. approval in 2015. Glycopyrrolate was an established active ingredient before the product’s approval, so the principal exclusivity analysis is patent-based rather than dependent on a new-chemical-entity period.[1]

Exclusivity category	Relevance to SEEBRI NEOHALER
New chemical entity exclusivity	Generally not the primary protection because glycopyrrolate was previously known
New dosage-form or clinical-study exclusivity	Depends on the specific FDA determination and approved labeling
Orange Book patents	Potentially material to ANDA timing
Device protection	May affect substitutable inhaler design
Formulation and process patents	May create additional barriers even when core product patents expire
Pediatric extension	Applies only if granted and reflected in FDA records

A generic applicant can file an ANDA with a Paragraph IV certification against an unexpired listed patent. A Paragraph IV notice can trigger patent litigation and, if suit is filed within the statutory period, a 30-month stay of FDA approval under the Hatch-Waxman framework.[3]

The commercially relevant date is not simply the earliest patent expiration. It is the earliest date on which a generic can obtain approval and launch without an operative patent injunction, settlement restriction or device-access problem.

What Paragraph IV challenges and litigation affect SEEBRI NEOHALER?

Publicly available regulatory records identify the NDA and product, but a complete litigation assessment requires matching every current Orange Book listing to district-court dockets and settlement terms.[1,2] The principal litigation questions are:

• Whether an ANDA has been filed against NDA 207923.
• Which listed patents received Paragraph IV certifications.
• Whether Novartis sued within the 45-day period.
• Whether a 30-month stay was imposed.
• Whether the case was dismissed, settled or adjudicated.
• Whether a settlement includes a licensed launch date.
• Whether the settlement covers only glycopyrrolate monotherapy or also combination products.

For this product class, litigation risk is usually concentrated in formulation and device claims rather than the broad concept of inhaled glycopyrrolate. A generic that uses the same capsule architecture and a closely comparable lactose blend may face higher claim-overlap risk than a developer using a distinct carrier system and inhaler platform.

What FDA regulatory pathway applies to generic SEEBRI NEOHALER?

The expected U.S. pathway is an ANDA under section 505(j), provided the applicant can establish pharmaceutical equivalence and bioequivalence to the reference product.[3] Inhalation powders require more than matching the active ingredient and strength.

A development package typically must address:

• Same active ingredient and dosage form.
• Same route of administration.
• Same nominal strength.
• Equivalent dose-count and container configuration.
• Delivered-dose uniformity.
• Aerodynamic particle-size distribution.
• Fine-particle dose.
• Device resistance and flow-rate performance.
• Capsule emptying.
• Moisture protection.
• Stability.
• Labeling and use instructions.

Systemic pharmacokinetic bioequivalence may not fully capture local pulmonary performance. FDA’s product-specific guidance and inhalation-drug guidance are therefore important for selecting comparative tests.[4,5]

A capsule-based generic may use the reference Neohaler device, a device that is functionally equivalent, or a different device if the regulatory strategy supports equivalent performance and labeling. Device substitution can create a larger development burden but may avoid direct dependence on a proprietary inhaler platform.

What commercial opportunities exist for SEEBRI NEOHALER excipients?

Low-cost reference-like generic

The lowest-risk opportunity is a lactose-based formulation designed to match the reference product’s performance. The commercial advantage is a familiar excipient system and a more straightforward regulatory argument. The limitation is weak differentiation and potential exposure to overlapping formulation claims.

Lactose-free glycopyrrolate inhaler

A lactose-free product could target patients and prescribers concerned about lactose or milk-protein residues. The opportunity is clinically narrow because the amount of lactose is small and most patients tolerate inhaled lactose-containing products. The product could still obtain commercial value through institutional formularies, patient preference and combination-product positioning.

Improved high-humidity formulation

Dry-powder inhalers are sensitive to humidity. Moisture can increase cohesion, reduce powder flow and alter capsule emptying. A carrier or packaging system optimized for humid markets could improve geographic performance in Latin America, Southeast Asia, India and other high-humidity regions.

The opportunity is strongest where packaging, storage and supply-chain conditions make powder robustness commercially important.

Combination inhalers

Glycopyrrolate is more commercially attractive in combination products than as a standalone LAMA. Relevant opportunities include:

• Glycopyrrolate plus a long-acting beta-2 agonist.
• Glycopyrrolate plus an inhaled corticosteroid and a long-acting beta-2 agonist.
• Glycopyrrolate in once-daily fixed-dose combinations.
• Common-device platforms that reduce patient handling steps.

Combination products create new formulation and patent claims. They also raise segregation, blend uniformity and dose-delivery challenges because each active may have different particle properties and dose levels.

Contract development and manufacturing

Companies with micronization, spray drying, capsule filling, inhaler assembly and analytical aerosol testing capabilities can offer development or manufacturing services. The most defensible capabilities are:

• Low-dose blend uniformity.
• Inhalation-grade carrier qualification.
• Device-specific capsule filling.
• Humidity-controlled processing.
• Aerodynamic particle-size testing.
• Comparative in vitro performance packages.

How strong is the SEEBRI NEOHALER patent estate?

The estate should be assessed as a layered inhalation platform rather than as a single active-ingredient patent.

Layer	Expected competitive significance
Glycopyrrolate active ingredient	Limited if based on historic compound claims
Micronized-particle specifications	Medium to high if narrowly drafted and difficult to design around
Lactose carrier formulation	Medium, depending on claim breadth and expiration
Capsule-device combination	High for products dependent on the same inhaler architecture
Method-of-use claims	Variable, depending on approved indication and claim scope
Combination inhalers	High because new formulations and dosing regimens can generate later-filed patents
Manufacturing processes	Medium, particularly where process parameters control aerosol performance

Patent strength depends on claim construction, prosecution history, written description, enablement and the availability of noninfringing alternatives. A formulation patent that requires a specific lactose grade, active-particle distribution and emitted-dose profile may be technically difficult to avoid but also vulnerable if the claim lacks a defensible link between the parameter and clinical performance.

Which companies are challenging the SEEBRI NEOHALER market?

The competitive field includes:

• Generic inhaler manufacturers developing glycopyrrolate capsules.
• Established respiratory companies with LAMA/LABA portfolios.
• Device companies licensing capsule-based dry-powder platforms.
• Contract manufacturers with micronization and inhalation filling capacity.
• Developers of nebulized glycopyrrolate products.
• Combination-product companies using glycopyrrolate as the LAMA component.

The most credible challengers are companies that already have an approved inhalation platform, analytical aerosol laboratories and a device strategy. A tablet or injectable generics company without inhalation experience faces a materially higher execution risk.

What revenue exposure and launch scenarios apply?

SEEBRI NEOHALER’s standalone revenue opportunity is constrained by competition from other LAMAs and by the greater commercial value of fixed-dose combinations. The principal launch scenarios are:

Scenario	Market effect
Reference-like generic after patent clearance	Rapid price erosion and formulary substitution
Limited generic entry	Moderate erosion with preserved brand or authorized-generic pricing
Device-constrained entry	Delayed uptake despite regulatory approval
Lactose-free differentiated entry	Smaller premium segment, limited broad substitution
Glycopyrrolate combination entry	Larger opportunity with higher development and patent risk
Regional licensing launch	Access to markets where Novartis branding or supply is limited

For a commercial buyer, the highest-value asset may not be the standalone SEEBRI NEOHALER equivalent. It may be the inhalation platform, device, excipient technology or glycopyrrolate combination program that can support multiple COPD products.

What geographic coverage matters for SEEBRI NEOHALER?

U.S. rights depend on FDA approval, Orange Book listings and U.S. patent status. European protection depends on national validations of European patents and local litigation. Other markets may have separate patent families, regulatory data protections and device-registration requirements.

The product is marketed under related names in different jurisdictions, including Seebri Breezhaler outside the United States. The active ingredient may be identified as glycopyrronium bromide rather than glycopyrrolate. Commercial diligence should therefore search both names, along with the device brand and the INN variants.

Key Takeaways

• SEEBRI NEOHALER uses a low-dose glycopyrrolate dry-powder formulation with lactose monohydrate as the principal carrier excipient.
• The key technical problem is not ingredient selection alone. It is controlling particle engineering, carrier detachment, capsule emptying and device-specific aerosol performance.
• A lactose-based generic is the lowest-risk formulation strategy.
• Lactose-free, humidity-robust and carrier-engineered products offer differentiation but require more extensive development.
• The strongest commercial opportunity is likely in glycopyrrolate combination inhalers rather than standalone monotherapy.
• Orange Book patents, device claims, unlisted formulation patents and Paragraph IV litigation must be analyzed together.
• An ANDA applicant must address aerodynamic performance and device behavior, not only conventional pharmaceutical equivalence.
• The most valuable enabling assets are inhalation manufacturing, low-dose blending, capsule filling and comparative aerosol analytics.

FAQs

Is lactose monohydrate essential to SEEBRI NEOHALER?

No. Lactose is the reference product’s principal carrier, but alternative inhalation-grade carriers or carrier-free engineered particles may be possible if they deliver comparable quality and performance.

Can a generic use a different inhaler from the Neohaler?

Potentially. A different device must support the required regulatory showing for dose delivery, aerodynamic performance, usability and labeling. Device patents and substitutability rules can affect the commercial strategy.

Is glycopyrrolate a small-molecule or biologic product?

Glycopyrrolate is a small molecule. Biosimilar regulation does not apply. Competition is generally pursued through an ANDA or, for materially different products, a 505(b)(2) application.

Does a lactose-free SEEBRI NEOHALER automatically receive a premium price?

No. Lactose-free status may support differentiation, but reimbursement, formulary placement, device usability and clinical preference determine whether the market will pay a premium.

What is the main manufacturing barrier for a SEEBRI NEOHALER generic?

The main barrier is reproducible delivery of a microgram-level dose from a capsule-based powder system. Low-dose blend uniformity, particle-size control, capsule emptying and fine-particle dose are the critical manufacturing risks.

References

1. U.S. Food and Drug Administration. (2015). SEEBRI NEOHALER prescribing information: Glycopyrrolate inhalation powder. Novartis Pharmaceuticals Corporation.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2022). ANDA submissions: Content and format.
4. U.S. Food and Drug Administration. (1998). Guidance for industry: Metered dose inhaler and dry powder inhaler drug products.
5. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.